img

Global Equine Influenza Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Equine Influenza Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Equine Influenza Vaccine market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Equine Influenza Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The China market for Equine Influenza Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034.
The Europe market for Equine Influenza Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2034, at a CAGR of % during the forecast period of 2023 through 2034..
The global key manufacturers of Equine Influenza Vaccine include Zoetis, Merck Animal Health and Boehringer Ingelheim Vetmedica, etc. In 2024, the global top five players hold a share approximately % in sales volume, and in term of revenue of Equine Influenza Vaccine, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Equine Influenza Vaccine by regions (Countries), company, by type and by type. from 2018 to 2023 and forecast to 2034.
The global Equine Influenza Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Equine Influenza Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Zoetis
Merck Animal Health
Boehringer Ingelheim Vetmedica
By Type
Liquid
Powder
By Application
Home
Pet Clinic
Others
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Equine Influenza Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Equine Influenza Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Equine Influenza Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Equine Influenza Vaccine Definition
1.2 Market by Type
1.2.1 Global Equine Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Liquid
1.2.3 Powder
1.3 Market Segment by Application
1.3.1 Global Equine Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Home
1.3.3 Pet Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Equine Influenza Vaccine Sales
2.1 Global Equine Influenza Vaccine Revenue Estimates and Forecasts 2018-2034
2.2 Global Equine Influenza Vaccine Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Equine Influenza Vaccine Revenue by Region
2.3.1 Global Equine Influenza Vaccine Revenue by Region (2018-2023)
2.3.2 Global Equine Influenza Vaccine Revenue by Region (2024-2034)
2.4 Global Equine Influenza Vaccine Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Equine Influenza Vaccine Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Equine Influenza Vaccine Sales Quantity by Region
2.6.1 Global Equine Influenza Vaccine Sales Quantity by Region (2018-2023)
2.6.2 Global Equine Influenza Vaccine Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Equine Influenza Vaccine Sales Quantity by Manufacturers
3.1.1 Global Equine Influenza Vaccine Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Equine Influenza Vaccine Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Equine Influenza Vaccine Sales in 2024
3.2 Global Equine Influenza Vaccine Revenue by Manufacturers
3.2.1 Global Equine Influenza Vaccine Revenue by Manufacturers (2018-2023)
3.2.2 Global Equine Influenza Vaccine Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Equine Influenza Vaccine Revenue in 2024
3.3 Global Equine Influenza Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Equine Influenza Vaccine, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Equine Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Equine Influenza Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Equine Influenza Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Equine Influenza Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Equine Influenza Vaccine Sales Quantity by Type
4.1.1 Global Equine Influenza Vaccine Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Equine Influenza Vaccine Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
4.2 Global Equine Influenza Vaccine Revenue by Type
4.2.1 Global Equine Influenza Vaccine Historical Revenue by Type (2018-2023)
4.2.2 Global Equine Influenza Vaccine Forecasted Revenue by Type (2024-2034)
4.2.3 Global Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
4.3 Global Equine Influenza Vaccine Price by Type
4.3.1 Global Equine Influenza Vaccine Price by Type (2018-2023)
4.3.2 Global Equine Influenza Vaccine Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Equine Influenza Vaccine Sales Quantity by Application
5.1.1 Global Equine Influenza Vaccine Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Equine Influenza Vaccine Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
5.2 Global Equine Influenza Vaccine Revenue by Application
5.2.1 Global Equine Influenza Vaccine Historical Revenue by Application (2018-2023)
5.2.2 Global Equine Influenza Vaccine Forecasted Revenue by Application (2024-2034)
5.2.3 Global Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
5.3 Global Equine Influenza Vaccine Price by Application
5.3.1 Global Equine Influenza Vaccine Price by Application (2018-2023)
5.3.2 Global Equine Influenza Vaccine Price Forecast by Application (2024-2034)
6 North America
6.1 North America Equine Influenza Vaccine Sales by Company
6.1.1 North America Equine Influenza Vaccine Revenue by Company (2018-2023)
6.1.2 North America Equine Influenza Vaccine Sales Quantity by Company (2018-2023)
6.2 North America Equine Influenza Vaccine Market Size by Type
6.2.1 North America Equine Influenza Vaccine Sales Quantity by Type (2018-2034)
6.2.2 North America Equine Influenza Vaccine Revenue by Type (2018-2034)
6.3 North America Equine Influenza Vaccine Market Size by Application
6.3.1 North America Equine Influenza Vaccine Sales Quantity by Application (2018-2034)
6.3.2 North America Equine Influenza Vaccine Revenue by Application (2018-2034)
6.4 North America Equine Influenza Vaccine Market Size by Country
6.4.1 North America Equine Influenza Vaccine Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Equine Influenza Vaccine Revenue by Country (2018-2034)
6.4.3 North America Equine Influenza Vaccine Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Equine Influenza Vaccine Sales by Company
7.1.1 Europe Equine Influenza Vaccine Sales Quantity by Company (2018-2023)
7.1.2 Europe Equine Influenza Vaccine Revenue by Company (2018-2023)
7.2 Europe Equine Influenza Vaccine Market Size by Type
7.2.1 Europe Equine Influenza Vaccine Sales Quantity by Type (2018-2034)
7.2.2 Europe Equine Influenza Vaccine Revenue by Type (2018-2034)
7.3 Europe Equine Influenza Vaccine Market Size by Application
7.3.1 Europe Equine Influenza Vaccine Sales Quantity by Application (2018-2034)
7.3.2 Europe Equine Influenza Vaccine Revenue by Application (2018-2034)
7.4 Europe Equine Influenza Vaccine Market Size by Country
7.4.1 Europe Equine Influenza Vaccine Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Equine Influenza Vaccine Revenue by Country (2018-2034)
7.4.3 Europe Equine Influenza Vaccine Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Equine Influenza Vaccine Sales by Company
8.1.1 China Equine Influenza Vaccine Sales Quantity by Company (2018-2023)
8.1.2 China Equine Influenza Vaccine Revenue by Company (2018-2023)
8.2 China Equine Influenza Vaccine Market Size by Type
8.2.1 China Equine Influenza Vaccine Sales Quantity by Type (2018-2034)
8.2.2 China Equine Influenza Vaccine Revenue by Type (2018-2034)
8.3 China Equine Influenza Vaccine Market Size by Application
8.3.1 China Equine Influenza Vaccine Sales Quantity by Application (2018-2034)
8.3.2 China Equine Influenza Vaccine Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Equine Influenza Vaccine Sales by Company
9.1.1 APAC Equine Influenza Vaccine Sales Quantity by Company (2018-2023)
9.1.2 APAC Equine Influenza Vaccine Revenue by Company (2018-2023)
9.2 APAC Equine Influenza Vaccine Market Size by Type
9.2.1 APAC Equine Influenza Vaccine Sales Quantity by Type (2018-2034)
9.2.2 APAC Equine Influenza Vaccine Revenue by Type (2018-2034)
9.3 APAC Equine Influenza Vaccine Market Size by Application
9.3.1 APAC Equine Influenza Vaccine Sales Quantity by Application (2018-2034)
9.3.2 APAC Equine Influenza Vaccine Revenue by Application (2018-2034)
9.4 APAC Equine Influenza Vaccine Market Size by Region
9.4.1 APAC Equine Influenza Vaccine Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Equine Influenza Vaccine Revenue by Region (2018-2034)
9.4.3 APAC Equine Influenza Vaccine Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Equine Influenza Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Equine Influenza Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Equine Influenza Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Equine Influenza Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Zoetis
11.1.1 Zoetis Company Information
11.1.2 Zoetis Overview
11.1.3 Zoetis Equine Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Zoetis Equine Influenza Vaccine Products and Services
11.1.5 Zoetis Equine Influenza Vaccine SWOT Analysis
11.1.6 Zoetis Recent Developments
11.2 Merck Animal Health
11.2.1 Merck Animal Health Company Information
11.2.2 Merck Animal Health Overview
11.2.3 Merck Animal Health Equine Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Merck Animal Health Equine Influenza Vaccine Products and Services
11.2.5 Merck Animal Health Equine Influenza Vaccine SWOT Analysis
11.2.6 Merck Animal Health Recent Developments
11.3 Boehringer Ingelheim Vetmedica
11.3.1 Boehringer Ingelheim Vetmedica Company Information
11.3.2 Boehringer Ingelheim Vetmedica Overview
11.3.3 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Products and Services
11.3.5 Boehringer Ingelheim Vetmedica Equine Influenza Vaccine SWOT Analysis
11.3.6 Boehringer Ingelheim Vetmedica Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Equine Influenza Vaccine Value Chain Analysis
12.2 Equine Influenza Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Equine Influenza Vaccine Production Mode & Process
12.4 Equine Influenza Vaccine Sales and Marketing
12.4.1 Equine Influenza Vaccine Sales Channels
12.4.2 Equine Influenza Vaccine Distributors
12.5 Equine Influenza Vaccine Customers
13 Market Dynamics
13.1 Equine Influenza Vaccine Industry Trends
13.2 Equine Influenza Vaccine Market Drivers
13.3 Equine Influenza Vaccine Market Challenges
13.4 Equine Influenza Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Equine Influenza Vaccine Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Liquid
Table 3. Major Manufacturers of Powder
Table 4. Global Equine Influenza Vaccine Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 5. Global Equine Influenza Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 6. Global Equine Influenza Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 7. Global Equine Influenza Vaccine Revenue Market Share by Region (2018-2023)
Table 8. Global Equine Influenza Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Equine Influenza Vaccine Revenue Market Share by Region (2024-2034)
Table 10. Global Equine Influenza Vaccine Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Doses)
Table 11. Global Equine Influenza Vaccine Sales by Region (2018-2023) & (K Doses)
Table 12. Global Equine Influenza Vaccine Sales Market Share by Region (2018-2023)
Table 13. Global Equine Influenza Vaccine Sales by Region (2024-2034) & (K Doses)
Table 14. Global Equine Influenza Vaccine Sales Market Share by Region (2024-2034)
Table 15. Global Equine Influenza Vaccine Sales Quantity by Manufacturers (2018-2023) & (K Doses)
Table 16. Global Equine Influenza Vaccine Sales Quantity Share by Manufacturers (2018-2023)
Table 17. Global Equine Influenza Vaccine Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 18. Global Equine Influenza Vaccine Revenue Share by Manufacturers (2018-2023)
Table 19. Global Equine Influenza Vaccine Price by Manufacturers 2018-2023 (USD/Dose)
Table 20. Global Key Players of Equine Influenza Vaccine, Industry Ranking, 2021 VS 2024
Table 21. Global Equine Influenza Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Equine Influenza Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Equine Influenza Vaccine as of 2024)
Table 23. Global Key Manufacturers of Equine Influenza Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Equine Influenza Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Equine Influenza Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Equine Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 28. Global Equine Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 29. Global Equine Influenza Vaccine Sales Quantity Share by Type (2018-2023)
Table 30. Global Equine Influenza Vaccine Sales Quantity Share by Type (2024-2034)
Table 31. Global Equine Influenza Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 32. Global Equine Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Equine Influenza Vaccine Revenue Share by Type (2018-2023)
Table 34. Global Equine Influenza Vaccine Revenue Share by Type (2024-2034)
Table 35. Equine Influenza Vaccine Price by Type (2018-2023) & (USD/Dose)
Table 36. Global Equine Influenza Vaccine Price Forecast by Type (2024-2034) & (USD/Dose)
Table 37. Global Equine Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 38. Global Equine Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 39. Global Equine Influenza Vaccine Sales Quantity Share by Application (2018-2023)
Table 40. Global Equine Influenza Vaccine Sales Quantity Share by Application (2024-2034)
Table 41. Global Equine Influenza Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 42. Global Equine Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Equine Influenza Vaccine Revenue Share by Application (2018-2023)
Table 44. Global Equine Influenza Vaccine Revenue Share by Application (2024-2034)
Table 45. Equine Influenza Vaccine Price by Application (2018-2023) & (USD/Dose)
Table 46. Global Equine Influenza Vaccine Price Forecast by Application (2024-2034) & (USD/Dose)
Table 47. North America Equine Influenza Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 48. North America Equine Influenza Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 49. North America Equine Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 50. North America Equine Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 51. North America Equine Influenza Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 52. North America Equine Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Equine Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 54. North America Equine Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 55. North America Equine Influenza Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 56. North America Equine Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Equine Influenza Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 58. North America Equine Influenza Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 59. North America Equine Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Equine Influenza Vaccine Sales Quantity by Country (2018-2023) & (K Doses)
Table 61. North America Equine Influenza Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 62. Europe Equine Influenza Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 63. Europe Equine Influenza Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 64. Europe Equine Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 65. Europe Equine Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 66. Europe Equine Influenza Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 67. Europe Equine Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Equine Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 69. Europe Equine Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 70. Europe Equine Influenza Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 71. Europe Equine Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Equine Influenza Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 73. Europe Equine Influenza Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 74. Europe Equine Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Equine Influenza Vaccine Sales Quantity by Country (2018-2023) & (K Doses)
Table 76. Europe Equine Influenza Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 77. China Equine Influenza Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 78. China Equine Influenza Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 79. China Equine Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 80. China Equine Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 81. China Equine Influenza Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 82. China Equine Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Equine Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 84. China Equine Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 85. China Equine Influenza Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 86. China Equine Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Equine Influenza Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 88. APAC Equine Influenza Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 89. APAC Equine Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 90. APAC Equine Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 91. APAC Equine Influenza Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 92. APAC Equine Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Equine Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 94. APAC Equine Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 95. APAC Equine Influenza Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 96. APAC Equine Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Equine Influenza Vaccine Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 98. APAC Equine Influenza Vaccine Revenue by Region (2018-2023) & (US$ Million)
Table 99. APAC Equine Influenza Vaccine Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Equine Influenza Vaccine Sales Quantity by Region (2018-2023) & (K Doses)
Table 101. APAC Equine Influenza Vaccine Sales Quantity by Region (2024-2034) & (K Doses)
Table 102. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Company (2018-2023) & (K Doses)
Table 103. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Company (2018-2023) & (US$ Million)
Table 104. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Type (2018-2023) & (K Doses)
Table 105. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Type (2024-2034) & (K Doses)
Table 106. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Type (2018-2023) & (US$ Million)
Table 107. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Application (2018-2023) & (K Doses)
Table 109. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Application (2024-2034) & (K Doses)
Table 110. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Application (2018-2023) & (US$ Million)
Table 111. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Country (2018-2023) & (US$ Million)
Table 114. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Country (2018-2023) & (K Doses)
Table 116. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity by Country (2024-2034) & (K Doses)
Table 117. Zoetis Company Information
Table 118. Zoetis Description and Overview
Table 119. Zoetis Equine Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 120. Zoetis Equine Influenza Vaccine Product and Services
Table 121. Zoetis Equine Influenza Vaccine SWOT Analysis
Table 122. Zoetis Recent Developments
Table 123. Merck Animal Health Company Information
Table 124. Merck Animal Health Description and Overview
Table 125. Merck Animal Health Equine Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 126. Merck Animal Health Equine Influenza Vaccine Product and Services
Table 127. Merck Animal Health Equine Influenza Vaccine SWOT Analysis
Table 128. Merck Animal Health Recent Developments
Table 129. Boehringer Ingelheim Vetmedica Company Information
Table 130. Boehringer Ingelheim Vetmedica Description and Overview
Table 131. Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Sales Quantity (K Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2018-2023)
Table 132. Boehringer Ingelheim Vetmedica Equine Influenza Vaccine Product and Services
Table 133. Boehringer Ingelheim Vetmedica Equine Influenza Vaccine SWOT Analysis
Table 134. Boehringer Ingelheim Vetmedica Recent Developments
Table 135. Key Raw Materials Lists
Table 136. Raw Materials Key Suppliers Lists
Table 137. Equine Influenza Vaccine Distributors List
Table 138. Equine Influenza Vaccine Customers List
Table 139. Equine Influenza Vaccine Market Trends
Table 140. Equine Influenza Vaccine Market Drivers
Table 141. Equine Influenza Vaccine Market Challenges
Table 142. Equine Influenza Vaccine Market Restraints
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Equine Influenza Vaccine Product Picture
Figure 2. Global Equine Influenza Vaccine Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Equine Influenza Vaccine Market Share by Type in 2024 & 2034
Figure 4. Liquid Product Picture
Figure 5. Powder Product Picture
Figure 6. Global Equine Influenza Vaccine Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 7. Global Equine Influenza Vaccine Market Share by Application in 2024 & 2034
Figure 8. Home
Figure 9. Pet Clinic
Figure 10. Others
Figure 11. Equine Influenza Vaccine Report Years Considered
Figure 12. Global Equine Influenza Vaccine Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 13. Global Equine Influenza Vaccine Revenue 2018-2034 (US$ Million)
Figure 14. Global Equine Influenza Vaccine Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 15. Global Equine Influenza Vaccine Sales Quantity 2018-2034 (K Doses)
Figure 16. Global Equine Influenza Vaccine Sales Quantity Market Share by Region (2018-2023)
Figure 17. Global Equine Influenza Vaccine Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Equine Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 19. North America Equine Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Equine Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 21. Europe Equine Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Equine Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 23. China Equine Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Equine Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 25. APAC Equine Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity YoY (2018-2034) & (K Doses)
Figure 27. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Equine Influenza Vaccine Sales Quantity in 2024
Figure 29. The Top 10 and Top 5 Players Market Share by Equine Influenza Vaccine Revenue in 2024
Figure 30. Equine Influenza Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 31. Global Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 33. Global Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 35. North America Equine Influenza Vaccine Revenue Market Share by Company in 2024
Figure 36. North America Equine Influenza Vaccine Sales Quantity Market Share by Company in 2024
Figure 37. North America Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 39. North America Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 41. North America Equine Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 42. North America Equine Influenza Vaccine Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Equine Influenza Vaccine Sales Quantity Market Share by Company in 2024
Figure 46. Europe Equine Influenza Vaccine Revenue Market Share by Company in 2024
Figure 47. Europe Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 49. Europe Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 51. Europe Equine Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 52. Europe Equine Influenza Vaccine Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 54. France Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 58. China Equine Influenza Vaccine Sales Quantity Market Share by Company in 2024
Figure 59. China Equine Influenza Vaccine Revenue Market Share by Company in 2024
Figure 60. China Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 62. China Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 64. APAC Equine Influenza Vaccine Sales Quantity Market Share by Company in 2024
Figure 65. APAC Equine Influenza Vaccine Revenue Market Share by Company in 2024
Figure 66. APAC Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 68. APAC Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 70. APAC Equine Influenza Vaccine Revenue Share by Region (2018-2034)
Figure 71. APAC Equine Influenza Vaccine Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 76. India Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity Market Share by Company in 2024
Figure 78. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue Market Share by Company in 2024
Figure 79. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Equine Influenza Vaccine Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Equine Influenza Vaccine Revenue Share by Country (2018-2034)
Figure 85. Brazil Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Equine Influenza Vaccine Revenue (2018-2034) & (US$ Million)
Figure 90. Equine Influenza Vaccine Value Chain
Figure 91. Equine Influenza Vaccine Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries